COMP <GO>
MREO vs SER // GROSS PROFIT MARGIN
Mereo BioPharma Group plc (NASDAQ) VS. Serina Therapeutics Inc. (NYSE) • 15-METRIC TALLY: MREO 2
— SER 2
■ METRIC PARITY
LAST: $0.30 (+1.62%) • MKT CAP: $48.2M
gross-margins
—
LAST: $1.89 (+15.24%) • MKT CAP: $48.0M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MREO VS. SER)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MREO | SER | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -60.00% | +128.00 | MREO | /net-margins <GO> |
| Revenue Growth (YoY) | — | 132.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | SER | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 49.8 | -2.80 | SER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.2M | $48.0M | $166.0K | MREO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MREO REV | SER REV | MREO GROSS % | SER GROSS % | MREO FCF | SER FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $500.0K | $130.0K | — | — | -$31.0M | -$18.0M |
| FY 2024 | $0 | $56.0K | — | — | -$32.8M | -$17.2M |
| FY 2023 | $10.0M | $3.2M | — | — | -$21.1M | -$2.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MREO // BETA —
SER // BETA —